Analysts expect Natera to report Q4 2025 revenue of approximately $600.7 million and an EPS loss of $0.50, with the stock currently trading near $200 compared to a $254 analyst price target.
The primary investor focus remains the clinical adoption and volume growth of Signatera, Natera's molecular residual disease (MRD) test, which is the key driver of its oncology segment.
Oncology test volumes have shown robust momentum, with recent data indicating that over 50% of U.S. oncologists now order the platform to monitor cancer recurrence.
Investors are also closely monitoring the company's trajectory toward cash flow positivity and the sustainability of its recent gross margin expansion.